Pleiotrophin affects the susceptibility of prostate cancer cells to cisplatin. Issue 2 (February 2022)

• Record Type: Journal Article
• Authors: Che, Qiuru; You, Liwei; Dai, Yumeng; Sun, Wei; Wang, Tao; Ding, Ke; Li, Yunfei; Zhang, Yuqiang; Ding, Linlin; Wang, Xingxing; Zhang, Zhuoqi; Li, Zhiwei; Yang, Liquan
• Is Part Of: Anti-cancer drugs. Volume 33:Issue 2(2022)
• Publication Date: 2022-02
• Subjects: apoptosis -- cisplatin -- pleiotrophin -- susceptibility·cancer; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000001259
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Drug resistance is a major problem in cancer therapy with cisplatin. It has not been reported that pleiotrophin, which is anti-apoptotic in some cancer cells, is associated with cisplatin resistance. Pleiotrophin was exogenously expressed in 293 cells. Viability and apoptosis of PC3 cells treated with different concentrations of cisplatin in the presence or absence of purified pleiotrophin were determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and flow cytometry, respectively. PC3 cells transfected with shRNAs were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) and western blotting 24 h after transfection. MTT assay data indicated that the EC50 value of cisplatin for PC3 cells was significantly increased in the presence of pleiotrophin. Flow cytometry data demonstrated the pleiotrophin dose-dependent anti-apoptosis in PC3 cells treated with cisplatin. Knockdown of pleiotrophin with sh-RNA, as justified by RT-PCR and western blotting analysis, led to increased cisplatin induced-apoptosis in PC3 cells with an increased level of the cleaved poly ADP-ribose polymerase protein. Pleiotrophin may be a potential antiapoptotic protein associated with cisplatin susceptibility, which warrants further study on the role of pleiotrophin in cisplatin resistance.